Identification of novel angiogenesis inhibitors.

Vascular endothelial growth factor (VEGF) is a key stimulant of angiogenesis, which is the process of generating new capillary blood vessels. Inhibition of the vascular endothelial growth factor receptor (VEGFR) kinase is known to result in blockage of angiogenesis. A pharmacophore was developed based on the binding of ATP to the hinge region of the kinase domain of VEGFR and a database search of 18,000 compounds was conducted. Selected hits were assessed for their ability to limit the induction of web-like network of capillary tubes by the human umbilical vascular endothelial cells. Two compounds (1 and 4) showed good inhibitory ability to prevent sprouting and closed polygon formation of the tubular networks, promising them to be lead compounds. Compound 4 showed 60% inhibition at 0.05 microM.

[1]  J. Mestan,et al.  Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. , 2004, Biochimica et biophysica acta.

[2]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[3]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[4]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[5]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[6]  S. Hubbard,et al.  Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. , 1997, Science.

[7]  U. Vanhoefer,et al.  Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. , 2003, Seminars in oncology.

[8]  G. Hortobagyi,et al.  Angiogenesis modulation in cancer research: novel clinical approaches , 2002, Nature Reviews Drug Discovery.

[9]  B. Ruggeri,et al.  A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clini , 2003, Journal of medicinal chemistry.

[10]  F. Rastinejad,et al.  Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. , 2003, Cancer research.

[11]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[12]  Y. Martin,et al.  3D database searching in drug design. , 1992, Journal of medicinal chemistry.

[13]  J. Mestan,et al.  Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. , 2002, Journal of medicinal chemistry.

[14]  M. Goldberg,et al.  Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.

[15]  B. Mroczkowski,et al.  Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. , 1999, Structure.

[16]  C. Lewis,et al.  Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. , 2000, Cancer research.

[17]  J. Madri,et al.  Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix , 1988, The Journal of cell biology.

[18]  A. Sali,et al.  Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.

[19]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[20]  P. Kollman,et al.  Atomic charges derived from semiempirical methods , 1990 .

[21]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[22]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[23]  D. Mooney,et al.  Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. , 1999, The American journal of pathology.